The US Food and Drug Administration (FDA) has approved the Trulign toric posterior chamber intraocular lens (IOL) from Bausch + Lomb, the company announced yesterday. The approval follows a favorable decision April 9 from the FDA's Ophthalmic Devices Panel. In a statement, Bausch + Lomb said the Trulign toric IOL is "intended for primary implantation in the capsular bag of the eye for the visual correction of aphakia and postoperative refractive astigmatism secondary to removal of a cataractous lens in adult patients with or without presbyopia who desire reduction of residual refractive cylinder with increased spectacle independence and improved uncorrected near, intermediate and distance vision." To see more details visit,www.medscape.com